Central Securities Corp.

Annual General Meeting of Materialise NV held at the registered office of the Company on Tuesday 16 June 2026 at 10:00 (CET): Resolutions

2026-07-01 16:05:00

LEUVEN, Belgium, July 01, 2026 (GLOBE NEWSWIRE) -- MATERIALISE NV Technologielaan 153001 LeuvenCompany number: 0441.131.254RPR Leuven

Invitation to Autoliv's Q2, 2026 Earnings Call

2026-06-24 09:59:00

STOCKHOLM, June 24, 2026 /PRNewswire/ -- Autoliv Inc., plans to publish its Financial Report for the second quarter 2026 on Friday, July 17, 2026 at 12:00 Central European Time (CET). The report will be available at www.autoliv.com In addition, a teleconference will take place the same day.

Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 9, 2026

2026-06-19 16:30:00

REGULATED INFORMATION June 19, 2026, 10:30pm CET / 4:30pm ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 9, 2026 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held on Thursday, July 9, 2026 at 2:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time.

Central Securities Corporation Declares Dividend

2026-06-01 16:05:00

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Central Securities Corporation (NYSE American: CET), a closed-end investment company, today declared the following dividend:   Class of Stock Rate Ex- and Record Date Payment Date     Common Stock $0.31 6/12/2026 6/26/2026   Of the $0.31 per share to be paid on June 26, 2026, $0.06 is expected to be taxable as ordinary income and $0.25 is expected to be taxable as long-term capital gain. The final tax breakdown of all amounts paid during 2026.

Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET

2026-05-13 02:58:00

STOCKHOLM, May 13, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's first quarter report for January - March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET. In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on May 20, at 9:30 a.m CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the first quarter report, followed by a Q&A session.

Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-06 16:01:00

Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM  (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026 Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation priorities Year-end 2026 cash and financial investments balance expected to be approximately €2B Management to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium ; May 6, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the first quarter of 2026 and provided a business update. “Having joined the company just one year ago, I'm thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines' talented team and its portfolio of programs to our Company, including the potential first and best in class T cell engager in autoimmune diseases, gamgertamig (OM336). We are excited that our Company is rebranding as Lakefront Biotherapeutics as this name reflects our Company's strategic evolution,” said Henry Gosebruch, Chief Executive Officer of Galapagos. Aaron Cox, Chief Financial Officer of Galapagos, added, “Following the anticipated use of cash to fund our collaboration with Gilead concerning its acquisition of Ouro Medicines, the Company will remain robustly capitalized and will have increased flexibility, including the ability to spend up to $500 million for business development independent of Gilead and not subject to our 2019 Option, License, and Collaboration Agreement with Gilead. This would also include the potential to use up to $150 million of that $500 million for share repurchases to the extent that we have available distributable reserves. In addition to the upfront consideration of $837.5 million, we anticipate additional 2026 Ouro-related cash expenditures to be in the range of €60-75 million, inclusive of R&D costs, one-time transaction costs and assuming a mid-year closing of the transaction.” First Quarter 2026 Business Update

Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results

2026-04-30 11:01:00

Press Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Central Securities Corporation Releases Report to Stockholders

2026-04-28 16:15:00

NEW YORK--(BUSINESS WIRE)--Central Securities Corporation (NYSE American: CET), a closed-end investment company, today released its Report to Stockholders for the three months ended March 31, 2026. Figures as of March 31, 2026 compared with those of one year ago, are as follows:   March 31, March 31,   2026 2025       Net assets per common share $58.94 $54.46       Net assets $1,741,512,380 $1,575,432,513       Shares outstanding 29,549,265 28,927,937 Additional details are available at www.cen.